Comparing the clinical efficacy of COVID-19 vaccines: a systematic review and network meta-analysis

V Rotshild, B Hirsh-Raccah, I Miskin, M Muszkat… - Scientific reports, 2021 - nature.com
Abstract New Coronavirus Disease 2019 (COVID-19) vaccines are available to prevent the
ongoing severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic. We …

Azithromycin in the treatment of COVID-19: a review

D Echeverría-Esnal, C Martin-Ontiyuelo… - Expert review of anti …, 2021 - Taylor & Francis
Introduction SARS-CoV-2 is a novel virus that causes coronavirus disease-19 (COVID-19).
Antiviral and immunomodulatory agents have been proposed as potential treatments …

ACG clinical guideline: gastroparesis

M Camilleri, B Kuo, L Nguyen, VM Vaughn… - Official journal of the …, 2022 - journals.lww.com
Gastroparesis is characterized by symptoms suggesting retention of food in the stomach with
objective evidence of delayed gastric emptying in the absence of mechanical obstruction in …

Update on the adverse effects of antimicrobial therapies in community practice

S Mohsen, JA Dickinson, R Somayaji - Canadian Family Physician, 2020 - cfp.ca
Objective To gather information about antibiotic side effects to be used as a reference and
learning resource for prescribing physicians. Quality of evidence A search of websites of …

Macrolides and viral infections: focus on azithromycin in COVID-19 pathology

A Pani, M Lauriola, A Romandini… - International journal of …, 2020 - Elsevier
The emergence of the new COVID-19 virus is proving to be a challenge in seeking effective
therapies. Since the most severe clinical manifestation of COVID-19 appears to be a severe …

Risk evaluation of azithromycin‐induced QT prolongation in real‐world practice

Y Choi, HS Lim, D Chung, J Choi… - BioMed research …, 2018 - Wiley Online Library
Background. Azithromycin exposure has been reported to increase the risk of QT
prolongation and cardiovascular death. However, findings on the association between …

Arrhythmic profile and 24-hour QT interval variability in COVID-19 patients treated with hydroxychloroquine and azithromycin

A Cipriani, A Zorzi, D Ceccato, F Capone… - International Journal of …, 2020 - Elsevier
Background Hydroxychloroquine and azithromycin combination therapy is often prescribed
for coronavirus disease 2019 (COVID-19). Electrocardiographic (ECG) monitoring is …

Immunomodulation by macrolides: therapeutic potential for critical care

TDY Reijnders, A Saris, MJ Schultz… - The Lancet Respiratory …, 2020 - thelancet.com
Critical illness is associated with immune dysregulation, characterised by concurrent
hyperinflammation and immune suppression. Hyperinflammation can result in collateral …

The gut microbiome and heart failure: a better gut for a better heart

M Branchereau, R Burcelin, C Heymes - Reviews in Endocrine and …, 2019 - Springer
Despite the development of new drugs and therapeutic strategies, mortality and morbidity
related to heart failure (HF) remains high. It is also the leading cause of global mortality …

Efficacy and safety of COVID‐19 vaccines: A network meta‐analysis

AA Toubasi, TN Al‐Sayegh, YY Obaid… - Journal of Evidence …, 2022 - Wiley Online Library
Objective Several vaccines showed a good safety profile and significant efficacy against
COVID‐19. Moreover, in the absence of direct head to head comparison between COVID …